C. Manegold

2.1k total citations
36 papers, 1.6k citations indexed

About

C. Manegold is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, C. Manegold has authored 36 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in C. Manegold's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (10 papers) and Occupational and environmental lung diseases (9 papers). C. Manegold is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (10 papers) and Occupational and environmental lung diseases (9 papers). C. Manegold collaborates with scholars based in Germany, Netherlands and Belgium. C. Manegold's co-authors include Giuseppe Giaccone, C. Debruyne, Joachim von Pawel, U. Gatzemeier, Dianne Tomita, C. Ewen, B Lebeau, A Depierre, Genevieve Decoster and V. Trillet-Lenoir and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Radiology.

In The Last Decade

C. Manegold

35 papers receiving 1.6k citations

Peers

C. Manegold

ONCOL

PRM

NEURO

GENET

Renata Langfort Poland

Laura C. Cappelli United States

Richard Quek Singapore

Ana C. Xavier United States

R. Sylvester Belgium

Charles M. Shapiro United States

P. Harper United Kingdom

Isabelle Moullet France

Herbert Stöger Austria

Pınar Saip Türkiye

Renata Langfort Poland

C. Manegold

594 ×0.6

ONCOL

904 ×1.1

PRM

275 ×1.1

121 ×0.6

NEURO

63 ×0.3

GENET

Citations per year, relative to C. Manegold C. Manegold (= 1×) peers Renata Langfort

Countries citing papers authored by C. Manegold

Since Specialization

Citations

This map shows the geographic impact of C. Manegold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Manegold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Manegold more than expected).

Fields of papers citing papers by C. Manegold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Manegold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Manegold. The network helps show where C. Manegold may publish in the future.

Co-authorship network of co-authors of C. Manegold

This figure shows the co-authorship network connecting the top 25 collaborators of C. Manegold. A scholar is included among the top collaborators of C. Manegold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Manegold. C. Manegold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Santoro, Armando, Paolo Andrea Zucali, Mary O’Brien, et al.. (2007). Pemetrexed plus cisplatin (P plus CIS) or carboplatin (P plus CB) in chemonaive malignant pleural mesothelioma (MPM) patients (PTS): Results of the international expanded access program (EAP). Annals of Oncology. 18. 32–32. 1 indexed citations

Groen, Harry J.M., Jan P. van Meerbeeck, David Gilligan, et al.. (2005). The impact of giving neo-adjuvant chemotherapy for patients with non-small cell lung cancer (NSCLC) : data from the MRC LU22/NVALT/EORTC 08012 randomised clinical trial. European Journal of Cancer Supplements. 3(2). 323–324. 2 indexed citations

Gravenor, Donald, Donald Woytowitz, J. Mezger, et al.. (2005). CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study. Journal of Clinical Oncology. 23(16_suppl). 7039–7039. 17 indexed citations

Meerbeeck, Jan P. van, G. Kramer, Ted A.W. Splinter, et al.. (2005). Morbidity and mortality in the surgery arm of EORTC 08941 trial. European Respiratory Journal. 26(2). 192–197. 66 indexed citations

Meerbeeck, Jan P. van, C. Manegold, Rabab Gaafar, et al.. (2004). A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC. Journal of Clinical Oncology. 22(14_suppl). 7021–7021. 25 indexed citations

Schottelius, J., et al.. (2003). Disseminierte Mikrosporidieninfektion (Encephalitozoon intestinalis) bei HIV-Infektion. DMW - Deutsche Medizinische Wochenschrift. 128(34/35). 1769–1772. 3 indexed citations

Tjan‐Heijnen, Vivianne C. G., Sue Caleo, Pieter E. Postmus, et al.. (2003). Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Annals of Oncology. 14(2). 248–257. 19 indexed citations

Smit, Egbert F., P. Lianes, C. Debruyne, et al.. (2003). Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. Journal of Clinical Oncology. 21(21). 3909–3917. 281 indexed citations

Emri, Salih, et al.. (2003). Chemotherapy for malignant pleural mesothelioma: past results and recent developments. British Journal of Cancer. 88(2). 167–174. 81 indexed citations

10.

Manegold, C., et al.. (2002). Phase I dose-escalating study of raltitrexed (‘Tomudex’) and cisplatin in metastatic non-small cell lung cancer. Lung Cancer. 36(2). 183–189. 3 indexed citations

11.

Meerbeeck, Jan P. van, Paul Baas, C. Debruyne, et al.. (2002). A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. European Journal of Cancer. 38(6). 779–783. 23 indexed citations

12.

Herth, Felix, Holger Becker, C. Manegold, & P. Drings. (2001). Endobronchial Ultrasound (EBUS) – Assessment of a New Diagnostic Tool in Bronchoscopy for Staging of Lung Cancer. Oncology Research and Treatment. 24(2). 151–154. 41 indexed citations

13.

Manegold, C., Paul Baas, Hugo Schouwink, et al.. (2000). Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM). Lung Cancer. 29(1). 18–19. 15 indexed citations

14.

Manegold, C., et al.. (1999). Topotecan - A New Treatment Option in the Therapy of Brain Metastases of Lung Cancer. Frontiers of radiation therapy and oncology. 33. 354–363. 28 indexed citations

15.

Meerbeeck, Jan P. van, Paul Baas, C. Debruyne, et al.. (1999). A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer. 85(12). 2577–2582. 109 indexed citations

16.

Meerbeeck, Jan P. van, Paul Baas, C. Debruyne, et al.. (1999). A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer. 85(12). 2577–2582. 65 indexed citations

17.

Lazzarino, Mario, Ester Orlandi, Marco Paulli, et al.. (1997). Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients.. Journal of Clinical Oncology. 15(4). 1646–1653. 114 indexed citations

18.

Manegold, C., Bengt Bergman, A. Chemaissani, et al.. (1997). Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Annals of Oncology. 8(6). 525–529. 91 indexed citations

19.

Latz, D., et al.. (1997). Invasive thymoma: treatment with postoperative radiation therapy.. Radiology. 204(3). 859–864. 55 indexed citations

20.

Trillet-Lenoir, V., C. Manegold, Joachim von Pawel, et al.. (1993). Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer. 29(3). 319–324. 425 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact